Annual EBITDA
-$46.86 M
+$1.55 M+3.20%
December 31, 2023
Summary
- As of February 8, 2025, VIRX annual EBITDA is -$46.86 million, with the most recent change of +$1.55 million (+3.20%) on December 31, 2023.
- During the last 3 years, VIRX annual EBITDA has fallen by -$28.09 million (-149.68%).
- VIRX annual EBITDA is now -149.68% below its all-time high of -$18.77 million, reached on December 31, 2020.
Performance
VIRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.76 M
-$727.00 K-8.04%
September 30, 2024
Summary
- As of February 8, 2025, VIRX quarterly EBITDA is -$9.76 million, with the most recent change of -$727.00 thousand (-8.04%) on September 30, 2024.
- Over the past year, VIRX quarterly EBITDA has increased by +$2.93 million (+23.08%).
- VIRX quarterly EBITDA is now -143.98% below its all-time high of -$4.00 million, reached on September 30, 2020.
Performance
VIRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$39.67 M
+$1.75 M+4.24%
September 30, 2024
Summary
- As of February 8, 2025, VIRX TTM EBITDA is -$39.67 million, with the most recent change of +$1.75 million (+4.24%) on September 30, 2024.
- Over the past year, VIRX TTM EBITDA has increased by +$7.20 million (+15.36%).
- VIRX TTM EBITDA is now -798.46% below its all-time high of -$4.42 million, reached on March 31, 2020.
Performance
VIRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VIRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.2% | +23.1% | +15.4% |
| 3 y3 years | -149.7% | +23.1% | +15.4% |
| 5 y5 years | -149.7% | +23.1% | +15.4% |
VIRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.9% | -19.5% | +44.4% | at high | +65.2% |
| 5 y | 5-year | -149.7% | +58.9% | -144.0% | +87.7% | -798.5% | +65.2% |
| alltime | all time | -149.7% | +58.9% | -144.0% | +87.7% | -798.5% | +65.2% |
Viracta Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.76 M(+8.0%) | -$39.67 M(-4.2%) |
| Jun 2024 | - | -$9.04 M(+10.6%) | -$41.42 M(-5.5%) |
| Mar 2024 | - | -$8.17 M(-35.6%) | -$43.83 M(-6.5%) |
| Dec 2023 | -$46.86 M(-3.2%) | -$12.69 M(+10.2%) | -$46.86 M(+5.9%) |
| Sep 2023 | - | -$11.52 M(+0.7%) | -$44.25 M(-12.0%) |
| Jun 2023 | - | -$11.44 M(+2.1%) | -$50.29 M(+2.1%) |
| Mar 2023 | - | -$11.21 M(+11.2%) | -$49.25 M(+1.7%) |
| Dec 2022 | -$48.41 M | -$10.08 M(-42.6%) | -$48.41 M(-2.4%) |
| Sep 2022 | - | -$17.56 M(+68.8%) | -$49.58 M(+6.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$10.40 M(+0.3%) | -$46.76 M(+3.1%) |
| Mar 2022 | - | -$10.37 M(-7.8%) | -$45.35 M(-60.3%) |
| Dec 2021 | -$114.09 M(+507.9%) | -$11.25 M(-23.7%) | -$114.09 M(+4.7%) |
| Sep 2021 | - | -$14.74 M(+63.8%) | -$108.96 M(+10.9%) |
| Jun 2021 | - | -$9.00 M(-88.6%) | -$98.23 M(+5.1%) |
| Mar 2021 | - | -$79.11 M(+1193.1%) | -$93.46 M(+398.0%) |
| Dec 2020 | -$18.77 M | -$6.12 M(+52.9%) | -$18.77 M(+48.4%) |
| Sep 2020 | - | -$4.00 M(-5.5%) | -$12.65 M(+46.3%) |
| Jun 2020 | - | -$4.23 M(-4.1%) | -$8.65 M(+95.9%) |
| Mar 2020 | - | -$4.42 M | -$4.42 M |
FAQ
- What is Viracta Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Viracta Therapeutics?
- What is Viracta Therapeutics annual EBITDA year-on-year change?
- What is Viracta Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Viracta Therapeutics?
- What is Viracta Therapeutics quarterly EBITDA year-on-year change?
- What is Viracta Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Viracta Therapeutics?
- What is Viracta Therapeutics TTM EBITDA year-on-year change?
What is Viracta Therapeutics annual EBITDA?
The current annual EBITDA of VIRX is -$46.86 M
What is the all time high annual EBITDA for Viracta Therapeutics?
Viracta Therapeutics all-time high annual EBITDA is -$18.77 M
What is Viracta Therapeutics annual EBITDA year-on-year change?
Over the past year, VIRX annual EBITDA has changed by +$1.55 M (+3.20%)
What is Viracta Therapeutics quarterly EBITDA?
The current quarterly EBITDA of VIRX is -$9.76 M
What is the all time high quarterly EBITDA for Viracta Therapeutics?
Viracta Therapeutics all-time high quarterly EBITDA is -$4.00 M
What is Viracta Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VIRX quarterly EBITDA has changed by +$2.93 M (+23.08%)
What is Viracta Therapeutics TTM EBITDA?
The current TTM EBITDA of VIRX is -$39.67 M
What is the all time high TTM EBITDA for Viracta Therapeutics?
Viracta Therapeutics all-time high TTM EBITDA is -$4.42 M
What is Viracta Therapeutics TTM EBITDA year-on-year change?
Over the past year, VIRX TTM EBITDA has changed by +$7.20 M (+15.36%)